TScan Therapeutics

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The consensus price target hints at a 125% upside potential for TScan Therapeutics, Inc. (TCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know

Company to present poster on initial data from heme malignancies Phase 1 trial at the 65 th ASH Annual Meeting and Exposition; Company to host virtual KOL event on Monday, December 11, 2023, at 8:00 a.m. ET

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Solid tumor program uses separate screening protocol designed to identify patients in advance of treatment protocol; on track to enroll first patient in study this year

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

TScan Therapeutics is developing TCR T-cell therapies for cancer using a transposon-based T cell engineering method. The company aims to target a broader patient population by addressing a wide range of human leukocyte antigen (HLA) types. TScan has a partnership with Amgen and has a sufficient cash balance to last for 6-7 quarters.

TScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest

TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why

WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of six abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 1-5, 2023, both in San Diego, CA and virtually.

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

TSC-203-A0201 is TScan's fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy TSC-203-A0201 is TScan's fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

TScan Therapeutics, Inc. (TCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.63 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report interim data by year-end 2023

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients. The collaboration supports TScan's screening protocol for its Phase 1 solid tumor clinical trial which is designed to enable custo.

Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today announced that its Chief Financial Officer, Brian M. Silver, J.D., will be leaving the Company, effective July 21, 2023, to pursue a new opportunity at a leading advisory firm based in New York, where he lives with his family. Brian will continue to be available to provide strategic advice for the Company. The Company has initiated a search for a successor chief financial officer.

TScan Therapeutics Announces Transition of Chief Financial Officer

TSC-200-A0201 is TScan's third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target and HLA expression TSC-200-A0201 is TScan's third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target and HLA expression

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will be presenting a Trial in Progress (TIP) poster at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held from June 2-6, 2023, at McCormick Place in Chicago, Illinois and online.

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 23,287,134 shares of its voting common stock, at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its voting common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds to TScan from this offering, including the partial exercise of the underwriters' over allotment option, were approximately $140.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan.

TScan Therapeutics Announces Closing of Public Offering

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Jefferies Healthcare Conference being held at the Marriott Marquis in New York, NY on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time.

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant. In addition, TScan has granted the underwriters a 30-day option to purchase up to an additional 10,500,000 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to TScan from this offering are expected to be approximately $140.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by TScan, assuming no exercise of the underwriter's option to purchase additional shares of voting common stock. The offering is expected to close on or about May 31, 2023 for the voting common stock, and June 1, 2023 for the pre-funded warrants, in each case, settlement is subject to customary closing conditions.

TScan Therapeutics Announces Pricing of $140 Million Public Offering

WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of shares of voting common stock and, in lieu of voting common stock to investors that so choose, non-voting common stock and pre-funded warrants to purchase shares of common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by TScan. TScan intends to grant the underwriters a 30-day option to purchase additional shares of its voting common stock in an amount equal to 15% of the securities offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

TScan Therapeutics Announces Launch of Proposed Public Offering

WALTHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that its Board of Directors (the Board) has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer (CEO) of TScan and as a Class I Director of its Board, each effective as of May 24, 2023. Dr. MacBeath, has been serving as acting CEO since March 2023. Dr. MacBeath will no longer serve as Chief Scientific and Operating Officer of the Company, effective May 24, 2023.

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.67 per share a year ago.

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

Entered into partnership with Amgen to identify novel targets in Crohn's disease; TScan to receive $30 million upfront

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

ClearOne

Mobiquity Technologies

Use these strategies to maximize your penny stocks profits The post 3 Top Strategies for Maximizing Penny Stock Profits Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Top Strategies for Maximizing Penny Stock Profits Right Now

Amgen

Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn's disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open.

News for TScan Therapeutics Stock (TCRX)